Limits...
Biological Character of RetroNectin Activated Cytokine-Induced Killer Cells.

Han L, Shang YM, Song YP, Gao QL - J Immunol Res (2016)

Bottom Line: Median survival time (mOS) after first R-CIK cell infusion was 10.57 months; the 1-year survival rate was 38.5%.No serious toxicity was associated with R-CIK cell infusion.In conclusion, RetroNectin may enhance antitumor activity of CIK cells: it is safe for use in treating pancreatic cancer.

View Article: PubMed Central - PubMed

Affiliation: Department of Immunology, Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, Henan 450008, China.

ABSTRACT
Adoptive cell therapy (ACT) using autologous cytokine-induced killer (CIK) cells is a promising treatment for metastatic carcinomas. In this study, we investigated the impact of RetroNectin on the proliferation, phenotype alternation, cytokine secretion, and cytotoxic activity of CIK cells from pancreatic cancer patients. Furthermore, we treated 13 patients with metastatic or locally advanced pancreatic cancer using autologous RetroNectin-activated CIK cells (R-CIK cells) alone or in combination with chemotherapy. Compared with only CD3 activated CIK cells (OKT-CIK cells), R-CIK cells showed stronger and faster proliferative ability, with a lower ratio of spontaneous apoptosis. Moreover, this ability continued after IL-2 was withdrawn from the culture system. R-CIK cells could also secrete higher levels of IL-2 and lower levels of IL-4 and IL-5 versus OKT-CIK cells. There was no difference between OKT-CIK and R-CIK cells in cytotoxic ability against lymphoma cell line K562. In patients who received auto-R-CIK cell infusion therapy, the overall objective response rate was 23.1%. Median survival time (mOS) after first R-CIK cell infusion was 10.57 months; the 1-year survival rate was 38.5%. No serious toxicity was associated with R-CIK cell infusion. In conclusion, RetroNectin may enhance antitumor activity of CIK cells: it is safe for use in treating pancreatic cancer.

No MeSH data available.


Related in: MedlinePlus

Composition of T subpopulation cells at different culture times. (a) CD3+CD4+ T cells cultured on the 10th and 16th day. (b) CD3+CD8+ T cells cultured on the 10th and 16th day. (c) CD3+CD56+ T cells cultured on the 10th and 16th day. (d) CD3+CD27+ T cells cultured on the 10th and 16th day. (e) CD3+CD28+ T cells cultured on the 10th and 16th day. (f) CD3+PD-1+ T cells cultured on the 10th and 16th day. CD3+CD4+ and CD3+CD28+ cells were higher in R-CIK cells, while CD3+CD56+ cells were lower in R-CIK cells on the 10th day, but they became equal on the 16th day. There was no difference seen between the OKT-CIK and R-CIK cells when compared to other subpopulation cells. As the culture time prolonged, CD3+CD8+ cell counts were raised in both OKT-CIK and R-CIK cells, and CD3+CD4+ cells decreased in both OKT-CIK and R-CIK cells at the same time. The % of the cells shows the % of cells in all cell population in the culture. ∗P < 0.05; ∗∗P < 0.01 for the comparison, n = 5.
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4940556&req=5

fig2: Composition of T subpopulation cells at different culture times. (a) CD3+CD4+ T cells cultured on the 10th and 16th day. (b) CD3+CD8+ T cells cultured on the 10th and 16th day. (c) CD3+CD56+ T cells cultured on the 10th and 16th day. (d) CD3+CD27+ T cells cultured on the 10th and 16th day. (e) CD3+CD28+ T cells cultured on the 10th and 16th day. (f) CD3+PD-1+ T cells cultured on the 10th and 16th day. CD3+CD4+ and CD3+CD28+ cells were higher in R-CIK cells, while CD3+CD56+ cells were lower in R-CIK cells on the 10th day, but they became equal on the 16th day. There was no difference seen between the OKT-CIK and R-CIK cells when compared to other subpopulation cells. As the culture time prolonged, CD3+CD8+ cell counts were raised in both OKT-CIK and R-CIK cells, and CD3+CD4+ cells decreased in both OKT-CIK and R-CIK cells at the same time. The % of the cells shows the % of cells in all cell population in the culture. ∗P < 0.05; ∗∗P < 0.01 for the comparison, n = 5.

Mentions: We analyzed the cell subpopulations in OKT-CIK and R-CIK cells cultured on the 10th and 16th days, including CD3+CD4+, CD3+CD8+, CD3+CD56+, CD3+CD27+, CD3+CD28+, and CD3+PD-1+ cells. As shown in Table 2 and Figure 2, the percentage of CD3+CD4+ cells and the percentage of CD3+CD28+ cells were higher in R-CIK cells on the 10th day (P < 0.05), but they became equal on the 16th day. Conversely, the percentage of CD3+CD56+ cells was lower in R-CIK cells on the 10th day (P < 0.05); it also became equal on the 16th day. There was no difference seen between the OKT-CIK and R-CIK cells when compared to other subpopulation cells (P > 0.05).


Biological Character of RetroNectin Activated Cytokine-Induced Killer Cells.

Han L, Shang YM, Song YP, Gao QL - J Immunol Res (2016)

Composition of T subpopulation cells at different culture times. (a) CD3+CD4+ T cells cultured on the 10th and 16th day. (b) CD3+CD8+ T cells cultured on the 10th and 16th day. (c) CD3+CD56+ T cells cultured on the 10th and 16th day. (d) CD3+CD27+ T cells cultured on the 10th and 16th day. (e) CD3+CD28+ T cells cultured on the 10th and 16th day. (f) CD3+PD-1+ T cells cultured on the 10th and 16th day. CD3+CD4+ and CD3+CD28+ cells were higher in R-CIK cells, while CD3+CD56+ cells were lower in R-CIK cells on the 10th day, but they became equal on the 16th day. There was no difference seen between the OKT-CIK and R-CIK cells when compared to other subpopulation cells. As the culture time prolonged, CD3+CD8+ cell counts were raised in both OKT-CIK and R-CIK cells, and CD3+CD4+ cells decreased in both OKT-CIK and R-CIK cells at the same time. The % of the cells shows the % of cells in all cell population in the culture. ∗P < 0.05; ∗∗P < 0.01 for the comparison, n = 5.
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4940556&req=5

fig2: Composition of T subpopulation cells at different culture times. (a) CD3+CD4+ T cells cultured on the 10th and 16th day. (b) CD3+CD8+ T cells cultured on the 10th and 16th day. (c) CD3+CD56+ T cells cultured on the 10th and 16th day. (d) CD3+CD27+ T cells cultured on the 10th and 16th day. (e) CD3+CD28+ T cells cultured on the 10th and 16th day. (f) CD3+PD-1+ T cells cultured on the 10th and 16th day. CD3+CD4+ and CD3+CD28+ cells were higher in R-CIK cells, while CD3+CD56+ cells were lower in R-CIK cells on the 10th day, but they became equal on the 16th day. There was no difference seen between the OKT-CIK and R-CIK cells when compared to other subpopulation cells. As the culture time prolonged, CD3+CD8+ cell counts were raised in both OKT-CIK and R-CIK cells, and CD3+CD4+ cells decreased in both OKT-CIK and R-CIK cells at the same time. The % of the cells shows the % of cells in all cell population in the culture. ∗P < 0.05; ∗∗P < 0.01 for the comparison, n = 5.
Mentions: We analyzed the cell subpopulations in OKT-CIK and R-CIK cells cultured on the 10th and 16th days, including CD3+CD4+, CD3+CD8+, CD3+CD56+, CD3+CD27+, CD3+CD28+, and CD3+PD-1+ cells. As shown in Table 2 and Figure 2, the percentage of CD3+CD4+ cells and the percentage of CD3+CD28+ cells were higher in R-CIK cells on the 10th day (P < 0.05), but they became equal on the 16th day. Conversely, the percentage of CD3+CD56+ cells was lower in R-CIK cells on the 10th day (P < 0.05); it also became equal on the 16th day. There was no difference seen between the OKT-CIK and R-CIK cells when compared to other subpopulation cells (P > 0.05).

Bottom Line: Median survival time (mOS) after first R-CIK cell infusion was 10.57 months; the 1-year survival rate was 38.5%.No serious toxicity was associated with R-CIK cell infusion.In conclusion, RetroNectin may enhance antitumor activity of CIK cells: it is safe for use in treating pancreatic cancer.

View Article: PubMed Central - PubMed

Affiliation: Department of Immunology, Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, Henan 450008, China.

ABSTRACT
Adoptive cell therapy (ACT) using autologous cytokine-induced killer (CIK) cells is a promising treatment for metastatic carcinomas. In this study, we investigated the impact of RetroNectin on the proliferation, phenotype alternation, cytokine secretion, and cytotoxic activity of CIK cells from pancreatic cancer patients. Furthermore, we treated 13 patients with metastatic or locally advanced pancreatic cancer using autologous RetroNectin-activated CIK cells (R-CIK cells) alone or in combination with chemotherapy. Compared with only CD3 activated CIK cells (OKT-CIK cells), R-CIK cells showed stronger and faster proliferative ability, with a lower ratio of spontaneous apoptosis. Moreover, this ability continued after IL-2 was withdrawn from the culture system. R-CIK cells could also secrete higher levels of IL-2 and lower levels of IL-4 and IL-5 versus OKT-CIK cells. There was no difference between OKT-CIK and R-CIK cells in cytotoxic ability against lymphoma cell line K562. In patients who received auto-R-CIK cell infusion therapy, the overall objective response rate was 23.1%. Median survival time (mOS) after first R-CIK cell infusion was 10.57 months; the 1-year survival rate was 38.5%. No serious toxicity was associated with R-CIK cell infusion. In conclusion, RetroNectin may enhance antitumor activity of CIK cells: it is safe for use in treating pancreatic cancer.

No MeSH data available.


Related in: MedlinePlus